Rafferty Asset Management
PTCT icon

Rafferty Asset Management’s PTC Therapeutics PTCT Stock Holding History

Rafferty Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.07M Sell
37,634
-31,051
-45% -$2.24M 0.01% 539
2026
Q1 		$4.68M Sell
68,685
-9,822
-13% -$696K 0.02% 402
2025
Q4 		$5.96M Sell
78,507
-22,494
-22% -$1.63M 0.02% 380
2025
Q3 		$6.2M Buy
101,001
+3,372
+3% +$176K 0.02% 381
2025
Q2 		$4.77M Buy
97,629
+40,562
+71% +$1.93M 0.02% 411
2025
Q1 		$2.91M Sell
57,067
-20,965
-27% -$1.05M 0.01% 486
2024
Q4 		$3.52M Sell
78,032
-23,231
-23% -$994K 0.01% 485
2024
Q3 		$3.76M Buy
101,263
+803
+0.8% +$26.9K 0.01% 479
2024
Q2 		$3.07M Sell
100,460
-193,844
-66% -$6.28M 0.01% 520
2024
Q1 		$8.56M Sell
294,304
-45,659
-13% -$1.28M 0.03% 326
2023
Q4 		$9.37M Buy
339,963
+133,676
+65% +$3.06M 0.04% 296
2023
Q3 		$4.62M Buy
206,287
+13,172
+7% +$490K 0.03% 400
2023
Q2 		$7.85M Buy
193,115
+35,672
+23% +$1.75M 0.04% 290
2023
Q1 		$7.63M Sell
157,443
-54,007
-26% -$2.47M 0.05% 257
2022
Q4 		$8.07M Buy
211,450
+82,292
+64% +$3.42M 0.07% 257
2022
Q3 		$6.48M Buy
129,158
+7,606
+6% +$373K 0.07% 254
2022
Q2 		$4.87M Sell
121,552
-37,838
-24% -$1.33M 0.04% 279
2022
Q1 		$5.95M Buy
159,390
+17,237
+12% +$664K 0.04% 334
2021
Q4 		$5.66M Buy
142,153
+62,662
+79% +$2.4M 0.03% 336
2021
Q3 		$2.96M Buy
79,491
+18,754
+31% +$770K 0.02% 485
2021
Q2 		$2.57M Buy
60,737
+3,733
+7% +$160K 0.02% 589
2021
Q1 		$2.7M Buy
57,004
+42,657
+297% +$2.53M 0.02% 547
2020
Q4 		$876K Sell
14,347
-29,166
-67% -$1.72M 0.01% 539
2020
Q3 		$2.03M Buy
43,513
+24,122
+124% +$1.19M 0.02% 412
2020
Q2 		$984K Buy
19,391
+12,361
+176% +$607K 0.01% 550
2020
Q1 		$314K Sell
7,030
-52,623
-88% -$2.65M 0.01% 425
2019
Q4 		$2.87M Sell
59,653
-29,771
-33% -$1.27M 0.04% 232
2019
Q3 		$3.02M Sell
89,424
-10,888
-11% -$474K 0.05% 231
2019
Q2 		$4.51M Sell
100,312
-9,754
-9% -$385K 0.08% 182
2019
Q1 		$4.14M Buy
+110,066
New +$3.7M 0.07% 167

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Rafferty Asset Management's PTCT Position: Q2 2026 in Review

Rafferty Asset Management reduced its PTC Therapeutics (PTCT) stake by 45% in Q2 2026, selling an estimated $2.24M and leaving 37,634 shares worth $3.07M. The position accounts for 0.01% of the portfolio, ranked #539.

Rafferty Asset Management first reported a position in PTCT in Q1 2019 and has held it in 30 quarters since. The position peaked at $9.37M in Q4 2023. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Rafferty Asset Management held 37,634 shares of PTC Therapeutics worth $3.07M as of Q2 2026.
  • Rafferty Asset Management sold 31,051 PTC Therapeutics shares in Q2 2026, an estimated $2.24M.
  • PTC Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #539 holding.
  • Rafferty Asset Management first reported a position in PTC Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • Rafferty Asset Management's PTC Therapeutics position peaked at $9.37M in Q4 2023.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.